JO3112B1 - تركيبة دوائية سريعة التحلل - Google Patents
تركيبة دوائية سريعة التحللInfo
- Publication number
- JO3112B1 JO3112B1 JOP/2011/0100A JOP20110100A JO3112B1 JO 3112 B1 JO3112 B1 JO 3112B1 JO P20110100 A JOP20110100 A JO P20110100A JO 3112 B1 JO3112 B1 JO 3112B1
- Authority
- JO
- Jordan
- Prior art keywords
- pharmaceutical composition
- fast dissolving
- dissolving pharmaceutical
- matrix network
- open matrix
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 229920001202 Inulin Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5062—Inulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الاختراع الحالي بتوفير تركيبة صيدلانية تشتمل على شبكة مصفوفة مفتوحة تحمل المكون النشط صيدلانياً، حيث تشتمل شبكة المصفوفة المفتوحة على إنولين.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN742DE2010 | 2010-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3112B1 true JO3112B1 (ar) | 2017-09-20 |
Family
ID=54241475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2011/0100A JO3112B1 (ar) | 2010-03-29 | 2011-03-22 | تركيبة دوائية سريعة التحلل |
Country Status (24)
Country | Link |
---|---|
US (2) | US10086078B2 (ar) |
EP (1) | EP2552403B1 (ar) |
JP (1) | JP5907945B2 (ar) |
KR (1) | KR101725173B1 (ar) |
CN (1) | CN102821755A (ar) |
AR (1) | AR080736A1 (ar) |
AU (1) | AU2011234636B2 (ar) |
BR (1) | BR112012024428A2 (ar) |
CA (1) | CA2793405A1 (ar) |
DK (1) | DK2552403T3 (ar) |
ES (1) | ES2553568T3 (ar) |
HK (1) | HK1181649A1 (ar) |
HU (1) | HUE026213T2 (ar) |
IL (1) | IL222086A (ar) |
JO (1) | JO3112B1 (ar) |
MX (1) | MX2012011204A (ar) |
NZ (1) | NZ602441A (ar) |
PL (1) | PL2552403T3 (ar) |
PT (1) | PT2552403E (ar) |
RU (1) | RU2566270C2 (ar) |
SA (1) | SA111320317B1 (ar) |
TW (1) | TWI513477B (ar) |
WO (1) | WO2011120903A2 (ar) |
ZA (1) | ZA201207176B (ar) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3254676T3 (pl) | 2009-10-30 | 2019-06-28 | Ix Biopharma Ltd | Szybko rozpuszczająca się stała postać dawkowana |
JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
CA2848785A1 (en) * | 2011-09-16 | 2013-03-21 | Ferring B.V. | A fast dissolving pharmaceutical composition |
TW201422254A (zh) * | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
CN106456535B (zh) * | 2014-04-25 | 2020-07-03 | R.P.谢勒技术有限公司 | 稳定的孟鲁司特溶液 |
EP3568124A1 (en) | 2017-01-11 | 2019-11-20 | Ferring B.V. | A fast disintegrating pharmaceutical composition |
CN111904936B (zh) * | 2020-08-28 | 2022-07-19 | 开封康诺药业有限公司 | 一种法莫替丁冻干粉针剂 |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA251629A (en) | 1925-07-14 | T. Hanna William | Coal cutting knife | |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4260602A (en) | 1977-08-16 | 1981-04-07 | Burroughs Wellcome Co. | Hapten polysaccharide conjugate medicaments and method of use |
CN1053808C (zh) | 1993-04-24 | 2000-06-28 | 章修纲 | 尼非地平控释剂型 |
EP0879600A1 (en) | 1997-05-20 | 1998-11-25 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Fructan containing composition for the prevention and treatment of colon cancer |
EP0958825A1 (en) * | 1998-05-18 | 1999-11-24 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer |
SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
WO2000025754A2 (en) | 1998-11-04 | 2000-05-11 | Mcneil-Ppc, Inc. | Solid oral dosage forms containing alginic acid and famotidine |
GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
NL1012300C2 (nl) * | 1999-06-11 | 2000-12-12 | Rijksuniversiteit | Stabilisator voor farmaca. |
EP1064938A1 (en) | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
EP1202716A1 (en) * | 1999-08-17 | 2002-05-08 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and process for making same |
WO2002003992A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
CN1556712A (zh) | 2000-07-13 | 2004-12-22 | ��һ��������ҩ��ʽ���� | 含dds化合物的药用组合物 |
IT1319664B1 (it) * | 2000-11-17 | 2003-10-23 | Pharma Biotech Ltd | Addotti di antibatterici chinolonici con polimeri polisaccaridicinaturali. |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
AU2003240759B2 (en) | 2002-04-03 | 2008-02-14 | Solvay Pharmaceuticals B.V. | Stabilized natural cannabinoid formulation |
BR0309819A (pt) | 2002-05-07 | 2005-03-01 | Ferring Bv | Formulações farmacêuticas |
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
AU2002314112A1 (en) * | 2002-05-27 | 2003-12-12 | Istituto Biochimico Pavese Pharma S.P.A | Dietary supplements from wine vinasses and relevant production process |
US20040096569A1 (en) | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
EP1428526A1 (en) * | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
JP4688787B2 (ja) | 2003-02-28 | 2011-05-25 | アルカベロ アクチェセルスカプ | 糖類マトリックスを有する剤形 |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
ES2300546T3 (es) | 2003-09-05 | 2008-06-16 | Myung-Jun Chung | Polvo de bacterias del acido lactico doblemente recubiertas usando proteina y polisacarido y metodo de preparacion del mismo y forma farmaceutica del mismo. |
CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
US20060088593A1 (en) | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
TW200621310A (en) * | 2004-11-10 | 2006-07-01 | Univ Groningen | A process for preparing formulations of lypophilic active substances by spray freeze drying |
CN100339081C (zh) * | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
CN101102748A (zh) * | 2004-12-23 | 2008-01-09 | 麦克内尔-Ppc股份有限公司 | 具有感觉提示剂的在口中分裂的药物组合物 |
US20070042023A1 (en) | 2005-08-22 | 2007-02-22 | National Starch And Chemical Investment Holding Corporation | Dissolvable film |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
TW200817049A (en) | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
EP2129385A2 (en) | 2007-03-27 | 2009-12-09 | The Procter & Gamble | Methods and kits for administering probiotics |
JP5269894B2 (ja) | 2007-06-27 | 2013-08-21 | ハンミ ファーム. シーオー., エルティーディー. | 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置 |
KR100930427B1 (ko) | 2008-01-25 | 2009-12-08 | 정명준 | 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품 |
US8623401B2 (en) | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
EP2318511B1 (en) * | 2008-08-28 | 2017-08-02 | Chr. Hansen A/S | Bacterial composition |
US8946153B2 (en) | 2010-03-29 | 2015-02-03 | Ferring B.V. | Fast dissolving pharmaceutical composition |
JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
US20120135050A1 (en) | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
CA2848785A1 (en) | 2011-09-16 | 2013-03-21 | Ferring B.V. | A fast dissolving pharmaceutical composition |
US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
-
2011
- 2011-03-22 JO JOP/2011/0100A patent/JO3112B1/ar active
- 2011-03-28 TW TW100110569A patent/TWI513477B/zh not_active IP Right Cessation
- 2011-03-28 MX MX2012011204A patent/MX2012011204A/es unknown
- 2011-03-28 PT PT117115261T patent/PT2552403E/pt unknown
- 2011-03-28 WO PCT/EP2011/054698 patent/WO2011120903A2/en active Application Filing
- 2011-03-28 HU HUE11711526A patent/HUE026213T2/en unknown
- 2011-03-28 PL PL11711526T patent/PL2552403T3/pl unknown
- 2011-03-28 KR KR1020127027215A patent/KR101725173B1/ko active IP Right Grant
- 2011-03-28 JP JP2013501779A patent/JP5907945B2/ja active Active
- 2011-03-28 BR BR112012024428A patent/BR112012024428A2/pt not_active IP Right Cessation
- 2011-03-28 CN CN2011800171635A patent/CN102821755A/zh active Pending
- 2011-03-28 US US13/638,121 patent/US10086078B2/en active Active
- 2011-03-28 EP EP11711526.1A patent/EP2552403B1/en active Active
- 2011-03-28 CA CA2793405A patent/CA2793405A1/en not_active Abandoned
- 2011-03-28 DK DK11711526.1T patent/DK2552403T3/en active
- 2011-03-28 ES ES11711526.1T patent/ES2553568T3/es active Active
- 2011-03-28 AU AU2011234636A patent/AU2011234636B2/en not_active Ceased
- 2011-03-28 NZ NZ602441A patent/NZ602441A/en not_active IP Right Cessation
- 2011-03-28 RU RU2012141141/15A patent/RU2566270C2/ru not_active IP Right Cessation
- 2011-03-29 AR ARP110101023A patent/AR080736A1/es unknown
- 2011-03-29 SA SA111320317A patent/SA111320317B1/ar unknown
-
2012
- 2012-09-23 IL IL222086A patent/IL222086A/en not_active IP Right Cessation
- 2012-09-25 ZA ZA2012/07176A patent/ZA201207176B/en unknown
-
2013
- 2013-07-31 HK HK13108936.5A patent/HK1181649A1/xx not_active IP Right Cessation
-
2018
- 2018-08-29 US US16/115,650 patent/US10512695B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SA111320317B1 (ar) | 2015-05-11 |
CN102821755A (zh) | 2012-12-12 |
KR20130008588A (ko) | 2013-01-22 |
ZA201207176B (en) | 2013-05-29 |
HUE026213T2 (en) | 2016-05-30 |
AU2011234636A1 (en) | 2012-10-11 |
AR080736A1 (es) | 2012-05-02 |
JP5907945B2 (ja) | 2016-04-26 |
MX2012011204A (es) | 2012-11-23 |
US10086078B2 (en) | 2018-10-02 |
TW201138830A (en) | 2011-11-16 |
EP2552403B1 (en) | 2015-09-09 |
US20180369392A1 (en) | 2018-12-27 |
BR112012024428A2 (pt) | 2016-05-31 |
US20130123180A1 (en) | 2013-05-16 |
US10512695B2 (en) | 2019-12-24 |
ES2553568T3 (es) | 2015-12-10 |
NZ602441A (en) | 2014-01-31 |
KR101725173B1 (ko) | 2017-04-10 |
AU2011234636B2 (en) | 2015-01-15 |
JP2013523676A (ja) | 2013-06-17 |
RU2012141141A (ru) | 2014-05-10 |
PL2552403T3 (pl) | 2016-01-29 |
EP2552403A2 (en) | 2013-02-06 |
IL222086A (en) | 2017-01-31 |
HK1181649A1 (en) | 2013-11-15 |
RU2566270C2 (ru) | 2015-10-20 |
WO2011120903A3 (en) | 2012-05-03 |
CA2793405A1 (en) | 2011-10-06 |
DK2552403T3 (en) | 2015-10-05 |
WO2011120903A2 (en) | 2011-10-06 |
PT2552403E (pt) | 2015-10-30 |
TWI513477B (zh) | 2015-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX341200B (es) | Composicion farmaceutica de disolucion rapida. | |
SA112330855B1 (ar) | تركيبة صيدلانية سريعة الذوبان | |
JO3112B1 (ar) | تركيبة دوائية سريعة التحلل | |
EP2522653A4 (en) | BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE | |
EP3216448B8 (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
MX2013012542A (es) | Compuestos de amida y aplicacion farmaceutica para el mismo. | |
LT2808325T (lt) | Pakeistieji azolai, antivirusinis aktyvus ingredientas, farmacinė kompozicija, jų gavimo ir panaudojimo būdas | |
CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
IN2015DN03984A (ar) | ||
MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
EP2394986A4 (en) | DERIVATIVES OF 3 AMINOXALYLAMINOBENZAMIDE AND INSECTICIDE AND MITICIDE AGENTS CONTAINING SAME AS ACTIVE INGREDIENT | |
TW200942524A (en) | Novel aminomethyl benzene derivatives | |
EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
TW200942530A (en) | Pyridine compounds | |
UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
MY152951A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
MX363530B (es) | Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo. | |
EA200900958A1 (ru) | Препарат невирапина пролонгированного высвобождения | |
MX339306B (es) | Agente anti-fungico. | |
EP2871187A4 (en) | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | |
EP2476420B8 (en) | Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same | |
WO2011156045A3 (en) | Tablet formulation of ezatiostat | |
TR201009399A2 (tr) | Hızlı çözünen efervesan rosuvastatin formülasyonları. | |
WO2010104485A3 (en) | Valsartan formulations |